^
    Back
    Association details:
    Biomarker:TMB-L + RB1 mutation
    Cancer:Urothelial Cancer
    Drug Class:Immunotherapy
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C3 – Early Trials
    Source:
    ASCO-GU 2023
    Title:

    Association of biomarkers and response to immune checkpoint inhibitors (ICIs) in patients with metastatic urothelial carcinoma (mUC) with high and low tumor mutation burden (TMB).

    Published date:
    02/13/2023
    Excerpt:
    Among TMB low pts, those with RB1 alterations had shorter mOS (11.3 months vs 17.2 months; p=0.04) compared to wild-type pts.
    DOI:
    10.1200/JCO.2023.41.6_suppl.534